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Mammalian DNA double-strand break repair protein XRCC4
interacts with DNA ligase IV
Susan E. Critchlow*†, Richard P. Bowater‡ and Stephen P. Jackson*†
Background: Mammalian cells deficient in the XRCC4 DNA repair protein are
impaired in DNA double-strand break repair and are consequently
hypersensitive to ionising radiation. These cells are also defective in site-
specific V(D)J recombination, a process that generates the diversity of antigen
receptor genes in the developing immune system. These features are shared by
cells lacking components of the DNA-dependent protein kinase (DNA-PK).
Although the XRCC4 gene has been cloned, the function(s) of XRCC4 in DNA
end-joining has remained elusive.
Results: We found that XRCC4 is a nuclear phosphoprotein and was an
effective substrate in vitro for DNA-PK. Human XRCC4 associated extremely
tightly with another protein(s) even in the presence of 1 M NaCl. Co-
immunoprecipitation and adenylylation assays demonstrated that this
associated factor was the recently identified human DNA ligase IV. Consistent
with this, XRCC4 and DNA ligase IV copurified exclusively and virtually
quantitatively over a variety of chromatographic steps. Protein mapping studies
revealed that XRCC4 interacted with ligase IV via the unique carboxy-terminal
ligase IV extension that comprises two tandem BRCT (BRCA1 carboxyl
terminus) homology motifs, which are also found in other DNA repair-associated
factors and in the breast cancer susceptibility protein BRCA1.
Conclusions: Our findings provide a function for the carboxy-terminal region of
ligase IV and suggest that BRCT domains of other proteins may mediate contacts
between DNA repair components. In addition, our data implicate mammalian
ligase IV in V(D)J recombination and the repair of radiation-induced DNA damage,
and provide a model for the potentiation of these processes by XRCC4. 
Background
One of the most dangerous forms of damage that can
befall a cell is the DNA double-strand break, which is the
principal lethal lesion induced by ionising radiation and
radiomimetic agents. Consequently, cells have evolved
highly effective systems for recognising this type of DNA
damage and ensuring that this damage is repaired effi-
ciently. Two major pathways have evolved to repair DNA
double-strand breaks in eukaryotes — homologous recom-
bination and DNA non-homologous end-joining — and
the available evidence suggests that both pathways are
highly conserved from yeast to man. Much of what is cur-
rently known about DNA non-homologous end-joining in
mammalian systems has been obtained from studies of
mutant rodent cell lines that are hypersensitive to ionising
radiation and display defects in DNA double-strand break
repair (reviewed in [1–3]). Characterisation of these cell
lines has revealed that they fall into three complementa-
tion groups, termed IR4, IR5 and IR7. The hamster cell
line XR-1 defines IR4, IR5 comprises several indepen-
dently isolated hamster cell mutants, and IR7 includes the
hamster cell line V3 and cells derived from the severe
combined immune-deficient (scid) mouse. The scid
immune defect arises through a deficiency in the DNA
non-homologous end-joining step of site-specific V(D)J
recombination — a genomic rearrangement process that
generates the vast range of antigen-binding sites of anti-
body and T-cell receptor proteins in developing lymphoid
cells [4,5]. Transient transfection studies have shown that
cells of the IR4 and IR5 groups are also defective in V(D)J
recombination. Together, these results reveal that the
genes defined by the IR4, IR5, and IR7 groups play
crucial roles in the repair of ionising radiation-induced
DNA damage and in the generation of antigen-binding
diversity in the vertebrate immune system. 
In light of the above findings, considerable effort has been
directed towards establishing the nature of the gene prod-
ucts that are defective in cells of the IR4, IR5 and IR7
complementation groups, and determining how they func-
tion in DNA non-homologous end-joining. Cells of the
IR5 and IR7 groups have been found to be deficient in
components of the DNA-dependent protein kinase
(DNA-PK). DNA-PK is a nuclear protein serine/threonine
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kinase that is activated upon binding to DNA double-
strand breaks or other perturbations of the DNA double-
helix [6]. DNA-PK is a multiprotein complex that can be
fractionated into two components: one of these compo-
nents confers a DNA end-binding activity and corre-
sponds to the heterodimeric Ku protein, comprising
subunits of approximately 70 kDa and 80 kDa (Ku70 and
Ku80, respectively); the other DNA-PK component, the
catalytic subunit (DNA-PKcs), is a polypeptide of
~465 kDa that, in association with DNA-bound Ku, medi-
ates DNA-PK kinase catalytic function [7]. Notably, cells
of the IR5 group lack DNA-PK activity because of a spe-
cific defect in Ku80 [8–11]. Conversely, cells of the IR7
group are deficient in DNA-PK activity because of the
absence of functional DNA-PKcs [12–14]. In contrast,
XR-1 cells of the IR4 group are not deficient in DNA-PK
activity [8,13,15,16]. Instead, DNA from human chromo-
some region 5q13–14 complements the deficiency in
XR-1 cells, and the complementing gene has been termed
XRCC4 [17]. Moreover, Li et al. [18] have identified the
XRCC4 gene by its ability to confer normal V(D)J recom-
bination activity and partially restore the double-strand
break repair defect in XR-1 cells, and have demonstrated
that the XRCC4 locus is deleted in XR-1 cells. XRCC4
encodes a small protein of 334 amino acid residues with a
calculated molecular weight of 38 kDa, and the human
and mouse XRCC4 homologues are approximately 75%
identical [18]. Sequence analyses have revealed that
XRCC4 is not significantly related to any previously char-
acterised proteins. Therefore, although XRCC4 plays a
crucial role in DNA double-strand break repair and V(D)J
recombination, the cloning and sequencing of the cDNA
for this factor have so far provided little information
regarding its mechanism of action. 
It appears highly unlikely that XRCC4, DNA-PKcs and
Ku80 are the only components of the mammalian DNA
double-strand break repair apparatus. Given that Ku80 is
invariably found in association with Ku70 and appears to
require Ku70 for DNA binding, it is predicted that Ku70
will also function in DNA double-strand break repair. In
addition, it is clear that a DNA ligase must act in DNA
non-homologous end-joining, yet sequence analyses
suggest that such a function is not mediated by DNA-
PKcs, Ku70, Ku80, or XRCC4. Mammalian cells contain at
least four biochemically distinct DNA ligases, termed
ligase I, II, III and IV and, although these enzymes have
similar catalytic domains, they have unique carboxy-termi-
nal and/or amino-terminal extensions and different func-
tional specificities in vitro. Evidence suggests that the
ligases perform specialised functions within the cell. For
example, whereas DNA ligase I plays an essential role in
joining Okazaki fragments during lagging-strand DNA
replication [19–22], DNA ligase III interacts with the
repair protein XRCC1 and is thought to function in DNA
base excision repair [23–26]. Furthermore, a testis-specific
splice variant of DNA ligase III is thought to play a role in
meiotic recombination [27,28]. At present, it is unknown
whether DNA ligase II arises from a separate gene or by
alternative splicing of the ligase III transcript, and the
physiological role for ligase II remains unclear [29–31].
Recent work has identified an additional mammalian
DNA ligase, termed ligase IV, that has distinct biochemi-
cal properties and substrate specificities from the other
ligases [23,32]; however, the biological function of DNA
ligase IV remains unknown. In this present study, we
show by a combination of immunological and biochemical
approaches that ligase IV associates tightly and specifically
with XRCC4. We discuss the implications of this finding
in terms of XRCC4 and ligase IV function and in relation
to the mechanism of DNA non-homologous end-joining. 
Results
Generation of antisera that recognise XRCC4
To investigate the mechanism of XRCC4 action, we
decided to characterise the human protein biochemically.
Full-length human XRCC4 and the carboxy-terminal
region of XRCC4 comprising residues 201–344 were
expressed in Escherichia coli as hexa-histidine-tagged pro-
teins (Figure 1a). After purification to homogeneity, each
protein was used as an immunogen to raise polyclonal
antisera in rabbits. During these studies, we observed that
recombinant full-length XRCC4 runs anomolously upon
SDS–PAGE with an apparent molecular mass of ~55 kDa,
which is considerably larger than the predicted molecular
weight of 38 kDa (for example, Figure 1b, lane 8 and
Figure 2b). Untagged and histidine-tagged versions of
XRCC4 behave similarly (data not shown). Although the
reason for this electrophoretic behaviour is not fully clear,
it may reflect the fact that XRCC4 contains a high propor-
tion of acidic residues, which may reduce the amount of
SDS bound to the protein and decrease its mobility upon
SDS–PAGE [33].
Western blot analyses revealed that each of the anti-
XRCC4 antisera raised could recognise less than 1 ng of
recombinant XRCC4 (data not shown and Figure 1b). To
establish whether these antisera could detect endogenous
XRCC4 in mammalian cell lysates, crude nuclear extracts
from HeLa cells were subjected to SDS–PAGE followed
by western immunoblot analysis. Each antiserum but
none of the pre-immune sera recognised a HeLa cell
protein of 55–60 kDa, in agreement with the size of
recombinant XRCC4 (Figure 1b; the band marked with an
asterisk probably represents an amino-terminal XRCC4
proteolytic product because it is recognised by all sera
raised against full-length XRCC4 but not by serum SJ5
which was raised against the XRCC4 carboxy-terminal
region). Interestingly, we have been unable to detect
XRCC4 in extracts of mouse or hamster cells by direct
western blotting using these antibodies (data not shown).
One possibility is that this reflects low immunological
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cross-reactivity between the human and rodent proteins.
Given the high degree of sequence conservation between
rodent and human XRCC4 [18], however, the model that
we favour is that XRCC4 is expressed at lower levels in
rodent cells than in human cells, as is the case for other
DNA double-strand break repair factors, such as Ku and
DNA-PKcs [13,34]. The specificity of anti-XRCC4 anti-
serum SJ4B was further enhanced by subjecting it to
immunoaffinity chromatography using XRCC4 covalently
attached to Sepharose beads. Significantly, whereas the
crude serum recognises a number of polypeptides in
HeLa whole cell extracts in addition to full-length
XRCC4 (Figure 1c, input), much of the reactivity towards
the other proteins is recovered only in the flow-through
fractions, resulting in the affinity-purified material
(eluate) having improved specificity and selectivity for
full-length XRCC4 compared with the unfractionated
serum (Figure 1c).
XRCC4 is a nuclear phosphoprotein and serves as an
effective substrate for DNA-PK in vitro
As a first step towards establishing the biochemical func-
tion of XRCC4, we determined its subcellular localisation.
Nuclear and cytosolic fractions were prepared from HeLa
cells and were subjected to western blot analysis using the
affinity-purified XRCC4 antibody SJ4B (Figure 2a). The
integrity of the fractions was established by additionally
probing with antiserum against Sp1, which is located pre-
dominantly in the nucleus. These studies revealed that
XRCC4 is present in the nuclear extract, with some
protein also being detectable in the cytosolic fraction. The
presence of XRCC4 in the nucleus is consistent with
models in which this factor serves as part of a DNA
double-strand break repair apparatus.
During the course of the above studies, we observed that
HeLa XRCC4 reproducibly migrated more slowly than
recombinant XRCC4 upon SDS–PAGE (for example,
Figures 1b and 2a), suggesting that human XRCC4 is
modified post-translationally. To determine whether this
is due to phosphorylation of XRCC4, HeLa nuclear
extract was either mock-treated, treated with λ protein
phosphatase, or treated with λ phosphatase in the pres-
ence of the phosphatase inhibitor sodium orthovanadate
(Figure 2b). Western analysis of these samples revealed
that treatment with λ phosphatase increased the elec-
trophoretic mobility of HeLa XRCC4 to that of the
recombinant protein, and this effect was abrogated by
treatment with the phosphatase inhibitor. These data
therefore reveal that XRCC4 is phosphorylated to a high
level in HeLa cell extracts and suggest that this modifica-
tion might modulate XRCC4 activity in vivo. In the light
of this phosphorylation and the similarity between
XRCC4-deficient cells and those defective in components
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Generation and purification of anti-XRCC4 antisera. (a) Generation of
antisera recognising full-length XRCC4 (residues 1–344) and the
XRCC4 carboxy-terminal domain (residues 201–344) to produce SJ4
(rabbits SJ4A/B/C) and SJ5, respectively. A representation of the
regions of XRCC4 to which antisera were raised is shown. (b)
Detection of XRCC4 in HeLa cell nuclear extracts. HeLa cell nuclear
extract (50 µg per lane; lanes 1–6,9,10) was subjected to western
immunoblot analysis using pre-immune (PI) or immune (I) sera derived
from rabbits SJ4A, SJ4B, SJ4C, or SJ5, as indicated. Each immune
serum recognises endogenous HeLa XRCC4 as a ~55 kDa protein.
Recombinant XRCC4 (5 ng) was also run alongside (lanes 7,8,11,12).
The position of XRCC4 is indicated by an arrow, and an asterisk marks
the position of a possible amino-terminal XRCC4 proteolytic product.
(c) Affinity purification of antiserum SJ4B. Crude SJ4B serum (input)
was passed over the XRCC4 affinity column. The depleted serum that
flowed through was collected (flow-through) and the column was then
washed extensively. Finally, bound antibody was eluted at low pH
(eluate). Samples of input, flow-through and eluate were tested for
their ability to detect XRCC4 in 50 µg of whole cell HeLa protein
extract by immunoblotting.
of DNA-PK, we tested whether DNA-PK could phospho-
rylate XRCC4 in vitro. As shown in Figure 2c, XRCC4 is
as an effective substrate for DNA-dependent phosphory-
lation by DNA-PK, suggesting that DNA-PK might
control XRCC4 activity.
Endogenous XRCC4 is complexed with another protein(s) 
There are various ways in which XRCC4 might function
in DNA double-strand break repair and V(D)J recombina-
tion. One possibility is that XRCC4 might interact directly
with DNA; however, we have been unable to detect
binding of recombinant XRCC4 to various DNA species
in electrophoretic mobility shift assays (data not shown).
Furthermore, when HeLa nuclear extracts are passed
through DNA–agarose columns under salt concentrations
that retain many DNA-binding proteins, the majority of
endogenous XRCC4 protein flows through the column
(data not shown). These data therefore argue that XRCC4
does not bind avidly to DNA. Another possible role for
XRCC4 is to interact with another component of the DNA
double-strand break repair apparatus. To address this pos-
sibility, we investigated the biochemical fractionation of
XRCC4 and other known and potential DNA double-
strand break repair factors upon gel-filtration chromatogra-
phy using a Superose-6 column. These experiments were
performed under stringent conditions of 1 M NaCl to
disrupt possible non-specific protein–protein associations.
The elution profile from gel-filtration analysis of pure
recombinant untagged XRCC4 was consistent with a mass
of around 100 kDa (Figure 3), which is larger than the pre-
dicted molecular weight of the XRCC4 monomer and its
apparent mass determined by SDS–PAGE (Figure 1b).
These data suggest that XRCC4 is either a monomeric
protein that behaves anomolously upon gel-filtration
analysis, or exists as a multimer.
Gel-filtration analysis of HeLa nuclear extract in the pres-
ence of 1 M NaCl revealed that endogenous XRCC4 frac-
tionated in a manner consistent with a molecular mass of
around 200 kDa, which is markedly higher than that of
recombinant XRCC4 (Figure 3). HeLa XRCC4 might
therefore be associated with another protein(s), possibly a
component of the double-strand break repair apparatus.
To evaluate this proposal, the same set of HeLa extract
gel-filtration fractions were examined for the presence of
Ku, DNA-PKcs, and DNA ligases I, III and IV. Although
some overlap was evident in each case, the XRCC4
elution profile did not parallel the profiles exhibited for
DNA ligase I or Ku (Figure 3 and data not shown): DNA
ligase I peaked at ~150 kDa, which is slightly larger than
the predicted monomer molecular weight of 102 kDa
(data not shown), and Ku elution peaked at ~150 kDa,
consistent with the predicted size of a Ku70/Ku80 hetero-
dimer. These data therefore argue against a stable interac-
tion between XRCC4 and DNA ligase I or Ku. XRCC4
had a similar elution profile to DNA-PKcs (465 kDa),
which eluted at a lower molecular weight than expected
(~200 kDa). Furthermore, the elution profile of XRCC4
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Figure 2
HeLa XRCC4 is a phosphoprotein and is phosphorylated efficiently by
DNA-PK in vitro. (a) XRCC4 is present in nuclear and cytoplasmic
extracts. Equivalent amounts (10µg) of nuclear and cytosolic extracts
were resolved by SDS–PAGE, and XRCC4 was detected by western
blotting with affinity-purified SJ4B antiserum. To determine the purity of
the extracts, blots were reprobed with an antibody against the
transcription factor Sp1, which is predominantly nuclear. (b) XRCC4 is
phosphorylated to high stoichiometry in HeLa cell nuclear extracts.
Untreated HeLa nuclear extract (50µg; lane 2), HeLa nuclear extract that
had been treated with λ protein phosphatase (lane 3), HeLa nuclear
extract that had been treated with λ protein phosphatase in the presence
of 0.1 µM, 1 µM, 10 µM, 0.1 mM and 1 mM of the phosphatase inhibitor
sodium orthovanadate (lanes 4–8), or recombinant XRCC4 as a size
control (lane 1) were analysed by immunoblotting using anti-XRCC4
antiserum (SJ4B), as indicated. (c) XRCC4 is phosphorylated by DNA-
PK in vitro in a DNA-dependent manner. DNA-PK was used in kinase
reactions containing either 50 ng of Sp1 or XRCC4 in the absence or
presence of linear DNA as indicated.
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was found to be virtually identical to those of DNA ligases
III and IV. These data therefore raise the possibility that
XRCC4 interacts stably with DNA-PKcs, DNA ligase III
or DNA ligase IV.
HeLa cell XRCC4 co-immunoprecipitates with DNA
ligase IV
To test for possible interactions between XRCC4 and the
factors described above, we immunoprecipitated XRCC4
from its peak gel-filtration fractions in the presence of 1 M
NaCl and 50 µg/ml ethidium bromide (to abolish non-spe-
cific interactions mediated via DNA), and examined
whether Ku, DNA-PKcs, and DNA ligases I, III, and IV
were present in the resulting precipitated material. Western
immunoblot analyses revealed that DNA-PKcs and Ku did
not co-immunoprecipitate with XRCC4 (Figure 4a). 
To assay for possible interactions between XRCC4 and a
DNA ligase, we utilised the fact that mammalian DNA
ligases form covalently-linked adenylate complexes
[23,32,35]. As shown in Figure 4b, incubation of the
XRCC4-containing gel-filtration fraction with α-[32P]ATP
led to the formation of adenylylated proteins of approxi-
mately 120 kDa and 100 kDa, which correspond to DNA
ligase I and a combination of DNA ligases III and IV,
respectively. To investigate the association between these
ligases and XRCC4, unlabelled extract was incubated with
pre-immune or anti-XRCC4 antisera in the presence of
1 M NaCl then, after stringent washing, the immunopre-
cipitated material was incubated with α-[32P]ATP and
tested for radioactively-labelled proteins. An adenylylated
protein species of ~100 kDa, corresponding to DNA ligase
III and/or IV was immunoprecipitated efficiently by the
affinity-purified XRCC4 antiserum but not by pre-
immune sera (Figure 4b); by contrast, the adenylylated
species corresponding to DNA ligase I was not recovered.
Consistent with the fact that the adenylate moiety of
adenylylated DNA ligase complexes is discharged in the
presence of ligatable polynucleotide substrates, the radio-
label associated with the XRCC4-precipitated material
was lost upon incubation with DNA that had been nicked
by DNase I treatment (data not shown). To exclude the
possibility that the immunoprecipitated ligase was recog-
nised directly by the anti-XRCC4 antiserum, we per-
formed parallel immunoprecipitation reactions on extracts
derived from the hamster cell lines K1 and XR-1, which
express XRCC4 and lack XRCC4, respectively. As shown
in Figure 4c, the ~100 kDa adenylylated ligase species
was recovered from K1 extracts but not from XR-1
extracts, revealing that the DNA ligase was not recognised
by the antiserum but instead was immunoprecipitated via
its association with XRCC4.
The above results show that XRCC4 forms a tight salt-
stable interaction with DNA ligase III and/or DNA ligase
IV. We were able to establish which of these two
enzymes was associated with XRCC4 because DNA
ligases III and IV have different abilities to join single-
strand breaks in polynucleotide substrates: whereas DNA
ligase III can catalyse joining in both oligo(rA)–poly(dT)
and oligo(dT)–poly(rA) substrates, DNA ligase IV is only
able to mediate joining of the latter [32]. We therefore
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Figure 3
Gel-filtration analysis of recombinant and
HeLa XRCC4. Recombinant untagged (Rec)
XRCC4 was loaded onto a Superose-6 gel
filtration column in the presence of 1 M NaCl.
Fractions were analysed by SDS–PAGE and
Coomassie-blue staining. An identical gel-
filtration run was performed with HeLa nuclear
extract and fractions were analysed by
immunoblotting with antibodies specific for
XRCC4, DNA ligase III, DNA ligase IV, Ku70,
Ku80 or DNA-PKcs. The elution profiles of the
molecular weight standards (Pharmacia)
ferritin (460 kDa), catalase (232 kDa),
aldolase (150 kDa) and albumin (67 kDa) are
indicated.
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performed adenylylation assays on material immuno-
precipitated with anti-XRCC4 antiserum and incubated the
labelled immunoprecipitates with either oligo(dT)–poly(rA)
or oligo(rA)–poly(dT). Only oligo(dT)–poly(rA) could disso-
ciate the adenylate group from the ligase that was immuno-
precipitated with XRCC4 (Figure 4b, compare lanes 4 and
5). These results therefore suggest that XRCC4 interacts
tightly and specifically with DNA ligase IV but not with
DNA ligase III.
XRCC4 and DNA ligase IV copurify extensively
To confirm the interaction between XRCC4 and DNA
ligase IV, and to determine the proportion of the two pro-
teins in the complex, we purified DNA ligase IV using
established protocols [32] and tested for the presence of
DNA ligase IV and XRCC4 at each chromatographic stage
by quantitative western immunoblot analyses. As demon-
strated previously, DNA ligases III and IV co-elute during
gel-filtration chromatography (Figures 3 and 5a) but can
be resolved by chromatography on Mono S (Figure 5b).
XRCC4 tracked with DNA ligase IV throughout these
purification procedures but was separated from DNA
ligase III at the Mono S chromatography step
(Figure 5a,b). XRCC4 was also present in more highly
purified samples of DNA ligase IV generated via subse-
quent chromatography on Mono Q (Figure 5c). In con-
trast, DNA ligase III was not present in the Mono
Q-purified samples of XRCC4 and DNA ligase IV (data
not shown). In additional studies, we observed that
XRCC4 and DNA ligase IV copurify on phenyl Sepharose
(data not shown). In fact, we have only been able to sepa-
rate these two proteins by incubation with harsh ionic
detergents. Interestingly, the XRCC4 protein that copuri-
fied with DNA ligase IV corresponded to the phosphory-
lated form as shown by its SDS–PAGE mobility and by
the fact that this mobility was increased by phosphatase
treatment (data not shown). XRCC4 and DNA ligase IV
copurified almost quantitatively, and no free pools of
either factor were evident (Figure 5a,b).
XRCC4 interacts with the carboxy-terminal region of DNA
ligase IV
To investigate the basis for the binding of DNA ligase IV
to XRCC4, we determined which region(s) of ligase IV
were involved in this interaction. As depicted in Figure 6a,
DNA ligase I, III and IV display high levels of sequence
similarity within the core ligase catalytic domain [23]. In
addition, each DNA ligase possesses discrete amino-termi-
nal and/or carboxy-terminal extensions that have been pro-
posed to confer unique properties on the three enzymes.
Significantly, although the carboxy-terminal extensions of
DNA ligases III and IV show very little homology with one
another at the primary sequence level, they possess one
and two copies, respectively, of the BRCA1 carboxyl termi-
nus (BRCT) homology domain that was recently identified
in the BRCA1 breast cancer susceptibility protein and a
series of other proteins ([36,37]; see Discussion).
To test which region(s) of DNA ligase IV interacts with
XRCC4, we divided the ligase IV protein into three parts:
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Figure 4
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XRCC4 co-immunoprecipitates with DNA ligase IV. (a) XRCC4 does
not co-immunoprecipitate DNA-PKcs or Ku80. Gel-filtration fraction 80
(lane 1) was subjected to immunoprecipitation using either pre-immune
serum (PI, lane 2), or affinity-purified XRCC4 antiserum (I, lane 3).
Precipitated proteins were resolved by SDS–PAGE and, after transfer
to nitrocellulose, filters were probed with antibodies raised against
DNA-PKcs or Ku80. (b) XRCC4 co-immunoprecipitates with a DNA
ligase. After immunoprecipitation with XRCC4 antiserum as in (a),
samples were incubated with α-[32P]ATP and, where indicated, then
further incubated with unlabelled polynucleotide substrate. Gel
filtration fraction 80 (lane 1), material precipitated with pre-immune
serum (PI, lane 2) or the material immunoprecipitated with anti-XRCC4
antiserum (I, lanes 3–5) were incubated with α-[32P]ATP, then
analysed by SDS–PAGE and autoradiography. Adenylylated proteins
were incubated with oligo(dT)–poly(rA) (lane 4) or oligo(rA)–poly(dT)
(lane 5) before electrophoresis. (c) Anti-XRCC4 antiserum
immunoprecipitates a protein that forms an adenylylated complex from
K1 but not XR-1 cells. K1 (lanes 1,2) or XR-1 (lanes 3,4) whole cell
extract was subjected to immunoprecipitation using either pre-immune
serum (PI, lanes 1,3) or affinity-purified anti-XRCC4 antiserum (I, lanes
2,4) prior to incubation with α-[32P]ATP.
an amino-terminal region (amino acid residues 1–198)
which exhibits homology with DNA ligase I and III; a
central region (amino acid residues 199–549) which shows
highest levels of homology with DNA ligase I and III and
contains the ligase catalytic site; and a carboxy-terminal
region (amino acid residues 550–844) which contains the
two BRCT homology domains (Figure 6a). The three
regions were transcribed and translated separately in vitro,
and tested for their ability to bind to Sepharose beads or to
Sepharose beads containing covalently attached XRCC4.
As shown in Figure 6b, the amino-terminal and central
fragments of DNA ligase IV failed to bind detectably to
the XRCC4–Sepharose beads, as was the case for the
luciferase protein used as a control. In marked contrast,
the ligase IV carboxy-terminal fragment was retained
almost quantitatively on the XRCC4–Sepharose beads but
not on control beads lacking XRCC4 (Figure 6b). More-
over, the binding of the carboxy-terminal portion of DNA
ligase IV to XRCC4 was very strong, as shown by the fact
that the ligase IV carboxy-terminal region was not eluted
by washing at 1 M NaCl (Figure 6b, lane 9) and was only
recovered following addition of the ionic detergent SDS
(Figure 6b, lane 10).
To further address the specificity of the above interaction,
we assessed whether XRCC4–Sepharose beads could be
used to purify the carboxy-terminal region of DNA
ligase IV from crude bacterial lysates. An unfractionated
extract from E. coli cells expressing fairly low levels of this
region of ligase IV was incubated with XRCC4–Sepharose
beads and the bound material was eluted with increasing
salt concentrations, followed by a final elution in the pres-
ence of SDS. As shown by total Coomassie-blue staining of
an SDS–polyacrylamide gel containing these fractions, this
method resulted in the purification of the carboxy-terminal
region of DNA ligase IV to virtual homogeneity in a single
step (Figure 6c; the identity of this polypeptide as the
ligase IV carboxyl terminus was confirmed by western blot-
ting, and this protein was not retained by Sepharose beads
alone). Taken together, these results demonstrate the
extreme strength and specificity of the interaction between
the ligase IV carboxy-terminal region and XRCC4.
Discussion
Previous work has established that cells deficient in
XRCC4 are hypersensitive to ionising radiation, defective
in DNA double-strand break rejoining and unable to
perform site-specific V(D)J recombination. Although
these findings reveal that XRCC4 plays a crucial role in
DNA double-strand break repair, its mechanism of action
has remained obscure. Another previously unresolved
question regarding DNA non-homologous end-joining is
which DNA ligase(s) is (are) involved. Here, we have
expressed XRCC4 in bacteria, raised antisera against this
factor and used these antisera to characterise endogenous
mammalian cell XRCC4. Consistent with XRCC4 serving
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Copurification of HeLa cell DNA ligase IV and XRCC4. Using the
protocol described previously [32], DNA ligase IV was purified from
HeLa cells. Fractions collected were analysed on SDS–polyacrylamide
gels and subjected to western blot analysis using anti-DNA ligase III,
anti-DNA ligase IV or anti-XRCC4 antisera. The amount of a specified
protein in each fraction was quantitated from densitometric scans of
the autoradiographs and the percentage of protein in each analysed
fraction (as a proportion of its total amount) was plotted. (a) XRCC4
and DNA ligase IV co-elute during gel-filtration chromatography.
Fraction 21 was loaded on to the Mono S column (see below). (b)
XRCC4 copurifies with DNA ligase IV but not DNA ligase III upon
Mono S chromatography. (c) XRCC4 is present in essentially pure
DNA ligase IV fractions. Samples 10 and 12, which had been further
purified by Mono Q chromatography [32], were analysed by
immunoblotting to test for the presence of XRCC4 (lanes 1,2) or DNA
ligase IV (lanes 3,4).
as a component of the DNA double-strand break repair
apparatus, we found that it was present in nuclear extracts.
Interestingly, however, we also detected a substantial pro-
portion of the XRCC4 protein in cytosolic fractions. More-
over, through a variety of approaches, we have
demonstrated that XRCC4 mediates extremely tight and
specific interactions with DNA ligase IV; for example,
these two components co-immunoprecipitated highly
specifically from HeLa cell extracts, even in the presence
of 1 M NaCl. These interactions were not abrogated by
ethidium bromide, suggesting that the interaction between
XRCC4 and DNA ligase IV is not mediated by a DNA
intermediate. Indeed, we have shown that bacterially
expressed XRCC4 and ligase IV bind to one another
tightly, revealing that their interaction is direct. In addi-
tion, XRCC4 and ligase IV copurified over every chromato-
graphic fractionation procedure we employed, and we have
only been able to resolve these two proteins by the addi-
tion of harsh ionic detergents.
The interaction of XRCC4 with DNA ligase IV but not
with other DNA ligases led us to investigate the basis for
this binding specificity. Although all characterised mam-
malian DNA ligases contain a common highly related core
catalytic region, each has unique amino-terminal and/or
carboxy-terminal extensions. Previous studies of DNA
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(a) Schematic representation of the various eukaryotic DNA ligases.
The core ligase catalytic domain is divided into two regions: the red
box indicates homology between DNA ligase I, III and IV and the green
box represents the highest levels of homology between the mammalian
DNA ligases and contains the catalytic site (active site) and conserved
peptide (indicated by solid white bars). The putative BRCT domains
[36,37] of DNA ligase III and IV are represented by blue boxes. (b)
Interaction between the carboxy-terminal portion of DNA ligase IV
comprising the BRCT domains and XRCC4. The fragments ligase IV
(1–198), ligase IV (199–549), ligase IV (550–844) and a luciferase
control were translated in the presence of [35S]methionine, then were
applied to XRCC4–Sepharose beads or negative control beads (load,
lanes 1,6) and unbound proteins were collected (FT, lanes 2,7). After
sequential washes with 0.1 M NaCl (lanes 3,8) and 1.0 M NaCl (lanes
4,9), bound proteins were eluted with SDS–gel loading buffer (SDS,
lanes 5,10). After SDS–PAGE, the [35S]methionine-labelled proteins
were detected by autoradiography. (c) Recombinant DNA ligase IV
(550–844) binds tightly and selectively to XRCC4. Bacterial extract
containing ligase IV (550–844) was applied to XRCC4–Sepharose
beads (load, lane 1) and unbound proteins collected (FT, lane 2). After
washes with stepwise increases of NaCl from 0–1.0 M (lanes 3–7),
proteins were eluted with SDS–gel loading buffer (SDS, lane 8).
ligases I and III have revealed that such regions are
involved in interactions with other factors. The amino-ter-
minal portion of DNA ligase I, for example, is important
for enzyme function in vivo and targets DNA ligase I to
specific nuclear structures termed replication factories
[38]. In addition, the carboxy-terminal extension of the
predominant form of mammalian DNA ligase III binds to
the DNA base excision repair factor XRCC1 [27,39]. In
line with these data, we have found that the unique
carboxy-terminal domain of DNA ligase IV interacts with
XRCC4. This region contains two tandem copies of the
BRCT homology domain [36,37], leading to the specula-
tion that either one or both of these domains mediates the
interaction with XRCC4. BRCT domains also exist in a
variety of other factors, including XRCC1, DNA ligase III,
and a group of yeast DNA repair and DNA-damage check-
point proteins [36,37]. It is noteworthy that the breast
cancer susceptibility protein BRCA1 contains a BRCT
domain and has been implicated recently in DNA repair
processes [40].
Given that XRCC4 functions in DNA non-homologous
end-joining, our data suggest that DNA ligase IV also plays
a crucial role in this process. Indeed, it is tempting to spec-
ulate that XRCC4 serves as a molecular bridge to link
DNA ligase IV with DNA double-strand breaks, perhaps
through additional interactions between XRCC4 and other
components of the DNA non-homologous end-joining
apparatus (Figure 7). XRCC4 could therefore function
analogously to XRCC1 which, in addition to interacting
with DNA ligase III, has been shown recently to bind to
the other DNA repair-associated factors DNA polymerase
β and poly-ADP-ribose polymerase [26,41]. In regard to a
putative bridging function for XRCC4, immunoprecipita-
tion studies suggest that XRCC4 can interact with Ku
and/or DNA-PKcs, although these interactions only occur at
low salt concentrations and hence are weak compared to
those between XRCC4 and DNA ligase IV (S.E.C. and
S.P.J., unpublished data). A possible physical linkage
between XRCC4 and DNA-PK is attractive in light of the
fact that HeLa XRCC4 is a phosphoprotein and is an effec-
tive substrate for DNA-PK in vitro. Consistent with the
proposal that ligase IV plays an important role in DNA
double-strand break repair, a Saccharomyces cerevisiae homo-
logue of DNA ligase IV has been identified recently
[42,43] and inactivation of this factor debilitates DNA non-
homologous end-joining in a manner that is epistatic with
mutations in the yeast homologues of Ku70 and Ku80
[43–46]. By contrast, yeast ligase IV does not play essential
roles in other DNA repair pathways that have been
analysed [42,43]. Taken together, the data therefore
suggest that ligase IV is dedicated to DNA non-homolo-
gous end-joining and that this function is conserved
throughout the eukaryotic kingdom. It therefore seems
likely that, as is the case for cells bearing mutations in
XRCC4 or DNA-PK components, disruption of the DNA
ligase IV gene in mammalian systems would result in defi-
cient V(D)J recombination and an inability to repair ionis-
ing radiation-induced DNA damage.
Conclusions
The XRCC4 protein is required for DNA non-homolo-
gous end-joining and V(D)J recombination in mammalian
cells. We have demonstrated that XRCC4 interacts tightly
and specifically with HeLa DNA ligase IV. The S. cere-
visiae homologue of DNA ligase IV has recently been
identified and found to be necessary for DNA non-homol-
ogous end-joining in yeast [42,43]. Taken together, these
findings strongly implicate DNA ligase IV in the joining of
double-strand breaks via the non-homologous end-joining
pathway and in the ligation steps of V(D)J recombination.
Furthermore, these data suggest that XRCC4 acts as a
molecular bridge to target DNA ligase IV to other compo-
nents of the DNA non-homologous end-joining apparatus.
Protein mapping studies revealed that XRCC4 interacts
with DNA ligase IV via its unique carboxy-terminal
domain. This domain contains two of the recently identi-
fied BRCT homology motifs found in other DNA repair-
associated factors and BRCA1, raising the intriguing
possibility that other BRCT domains may mediate con-
tacts between DNA repair components. 
Identification of components of the mammalian non-
homologous end-joining apparatus has been facilitated by
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Figure 7
Model in which XRCC4 serves as a molecular bridge to target DNA
ligase IV to a DNA double-strand break. In this model, Ku binds to the
free DNA ends and recruits DNA-PKcs, activating the kinase catalytic
function of the latter in the process. A DNA ligase IV–XRCC4 complex
is then recruited to the DNA double-strand break, either by direct
interactions with DNA-PKcs and/or Ku, or indirectly via other as yet
uncharacterised components of the double-strand break repair
machinery. Active DNA-PK may also trigger DNA-damage signalling
events or may phosphorylate other DNA double-strand break repair
components, such as XRCC4, thus regulating their activities. The
stoichiometry of the XRCC4–DNA ligase IV complex is currently
unknown but we have chosen to depict it as 2:1 because DNA
ligase IV has two BRCT homology domains.
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studies in cell lines that are defective in double-strand
break repair. Determination of the defects in these cell
lines has demonstrated that DNA-PKcs, Ku80 and XRCC4
are crucial for non-homologous end-joining. The strong
interaction between XRCC4 and DNA ligase IV represents
an advance in the identification of as yet unknown compo-
nents of the double-strand break repair apparatus and pro-
vides further insights into the mechanisms of detection and
removal of this dangerous form of DNA damage.
Materials and methods
Enzymes, antibodies and DNA
The pET-30b and pQE-30 vectors were obtained from Novagen and
Qiagen, respectively. All plasmid constructs were verified by automated
DNA sequencing (J. Lester; Biochemistry Department, University of
Cambridge). HeLa nuclear and cytoplasmic extracts were obtained
from Computer Cell Culture Centre, Mons, Belgium. 
Cell culture and preparation of whole cell extracts
The Chinese hamster ovary cell lines K1 (parental) and XR-1 were
maintained as monolayers at 37°C in a 5% CO2 atmosphere in minimal
essential medium supplemented with nonessential amino acids, peni-
cillin (100 U/ml), streptomycin (0.1 mg/ml), and 10% foetal calf serum.
Whole cell extracts were prepared as described [34]. 
Expression and purification of XRCC4 derivatives
To generate recombinant untagged XRCC4, the full-length XRCC4
coding region was amplified from pBlueScript containing the human
XRCC4 gene by PCR and inserted into pET-30a (Novagen) digested
with NdeI/SalI thereby removing the amino-terminal His/S tags; the
XRCC4 stop codon also prevents the addition of a carboxy-terminal
His-tag. BL21(DE3) cells were used to express the XRCC4 from the
plasmid (pET30XRCC4). After lysing by sonication, 30.2 g of ammo-
nium sulphate was added per 100 ml of supernatant and incubated
with stirring at 4°C for 30 min. After centrifugation, the pellet was
resuspended in TED (50 mM Tris-HCl pH 7.5, 2 mM DTT and 1 mM
EDTA) and dialysed against TED. The protein was then loaded onto a
heparin Sepharose column and protein was eluted with a 0–0.6 M
NaCl linear gradient. Fractions containing XRCC4 were pooled and
dialysed against TED containing 1.0 M ammonium sulphate and were
then loaded onto a phenyl Sepharose column. Proteins were eluted
with a 100 ml linear gradient of 1.0—0 M (NH4)2SO4. Fractions contain-
ing XRCC4 (typically 95% pure), eluting at ~0.2 M (NH4)2SO4, were
pooled and dialysed against 50 mM Tris-HCl pH 7.5, 2 mM DTT, 1 mM
EDTA and 10% (w/v) glycerol, and stored at –80°C. 
Anti-XRCC4 antibody production and purification
Regions of the XRCC4 gene were amplified by PCR and then inserted
in-frame downstream of the hexa-histidine (His) tag of pQE-30 (Qiagen)
and were expressed and purified according to the manufacturer’s
instructions from the soluble fraction of bacterial lysates. Antibodies
were raised in rabbits using standard procedures [47] and are available
commercially from Serotec, UK. Recombinant histidine-tagged full-
length XRCC4 was attached to Sulfolink Coupling Gel (Pierce) and was
used to carry out immunoaffinity purification of anti-XRCC4 antibodies
from crude SJ4 serum as described previously [48].
Phosphorylation assays
Phosphorylation assays were performed essentially as described in [7].
Assays contained 50 ng of Sp1 or recombinant untagged XRCC4,
100 ng of purified DNA-PK and 200 ng of linearized pBluescript as
indicated. 
Co-immunoprecipitations and ligase adenylylation assays
HeLa nuclear extract was dialysed into buffer D* (20 mM HEPES-KOH,
20% (w/v) glycerol, 50 mM KCl, 2 mM MgCl2, 0.2 mM EDTA, 1 mM
DTT, 0.5 mM PMSF, 1 mM sodium metabisulphite and 0.1% NP-40)
and then incubated with either pre-immune or anti-XRCC4 serum for
1 h at 4°C in the presence of 50 µg/ml ethidium bromide to disrupt
protein–DNA interactions [49]. Immune complexes were bound to
protein A Sepharose beads (Pharmacia), followed by extensive
washing with buffer D* containing 0.15–1 M NaCl. Protein A
Sepharose beads were finally washed in buffer D* containing 0.15 M
NaCl prior to analysis. Samples were then tested for the ability to form
DNA ligase-adenylylated complexes as described previously [32].
Polynucleotide substrates oligo(dT)–poly(rA) and oligo(rA)–poly(dT)
were prepared as described [35]. The reactivity of the enzyme–adeny-
late intermediates formed was examined by adding 0.8 µg of unlabelled
oligo(dT)–poly(rA) or oligo(rA)–poly(dT) for 1 h at 30°C. 
Gel-filtration chromatography
Total HeLa nuclear extract (6 mg protein) was dialysed extensively
against buffer A (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM DTT,
10% (w/v) glycerol) containing 1 M NaCl. Material was then loaded
onto a Superose 6 (Pharmacia) column (60 × 1.5 cm), pre-equilibrated
with buffer A containing 1 M NaCl. On an identical gel-filtration run,
0.2 mg of pure untagged recombinant XRCC4 was analysed in buffer
A containing 1 M NaCl.
Purification of DNA ligase IV from HeLa cells
DNA ligase IV was purified from HeLa cells as described previously [32].
Fractions collected from each column were analysed by immunoblots
with antibodies specific for XRCC4 and DNA ligases III and IV. 
Expression of recombinant ligase IV derivatives
Fragments of the human ligase IV gene coding region were amplified
by PCR from reverse-transcribed HeLa RNA. Each PCR product
included a BamHI site at the 5′ end and a stop codon followed by a
SalI site at the 3′ end. After digestion, the PCR products were ligated
into pET30b digested with BamHI/SalI. The 550–844 fragment of
ligase IV was also cloned into pQE-30 and the resulting clone was
expressed in E. coli M15(Rep4). For in vitro transcription and transla-
tion of ligase IV fragments, 1 µg of pET30LigIV(1–198),
pET30LigIV(199–549), pET30LigIV(550–844) or a luciferase control
(Promega) were transcribed in vitro and translated using the TnT rabbit
reticulocyte lysate kit (Promega) according to the manufacturer’s
instructions. The amino-terminally histidine-tagged ligase IV products
were then purified by Ni2+–NTA agarose chromatography.
Interaction assays between recombinant XRCC4 and ligase
IV derivatives
Full-length XRCC4 was immobilised on Sepharose-4B gel beads
(Pharmacia) using the cyanogen bromide method according to the
manufacturer’s instructions. As a negative control, coupling was per-
formed without XRCC4. A 30 µl bed volume of beads (with and
without XRCC4) was pre-equilibrated with binding buffer (50 mM Tris-
HCl pH 7.5, 2 mM DTT, 1 mM EDTA, 10% (w/v) glycerol, 0.1% NP-40
and 0.36 mg/ml BSA) before addition of the purified in vitro translated
ligase IV products or luciferase. Unbound material was collected after
centrifugation and beads were washed with binding buffer containing
0.1 M NaCl and 1.0 M NaCl. Proteins bound to the beads were then
analysed by SDS–PAGE and autoradiography. The ability of the
recombinant carboxy-terminal fragment of ligase IV (residues
550–844) to bind XRCC4–Sepharose was tested as above, except
that analysis was by Coomassie-blue staining and immunoblotting with
the anti-ligase IV antibody.
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